SS-31
A mitochondria-targeting tetrapeptide (elamipretide) that binds cardiolipin on the inner mitochondrial membrane; it has been tested in multiple human trials and gained FDA accelerated approval for the ultra-rare Barth syndrome in 2025, though several other primary endpoints were not met.
In plain English
SS-31, better known by its drug name elamipretide, is a small four-amino-acid peptide designed to home in on mitochondria, the energy factories inside cells. It sticks to a membrane fat called cardiolipin and is thought to help damaged mitochondria make energy more efficiently. Unlike most peptides sold for 'research,' SS-31 has been through real, large human clinical trials in serious diseases, including a rare genetic heart-and-muscle condition (Barth syndrome), broader mitochondrial muscle disease, dry age-related macular degeneration, and heart failure. The honest picture is mixed: many of these trials did NOT meet their main goals, but the Barth syndrome program produced enough signal that the FDA granted accelerated (conditional) approval in 2025. It is not an approved or proven therapy for general energy, anti-aging, or wellness use.
What it is
SS-31 is a synthetic, cell-permeable tetrapeptide with the sequence D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2. It is the same molecule developed pharmaceutically as elamipretide, and previously studied under the codes MTP-131 and the trial name Bendavia by Stealth BioTherapeutics. It is delivered by subcutaneous injection in clinical studies.
Mechanism (summary)
SS-31 carries a net positive charge that lets it concentrate inside mitochondria and bind selectively to cardiolipin, a phospholipid unique to the inner mitochondrial membrane. By associating with cardiolipin, it is proposed to stabilize the folded cristae architecture of the inner membrane, help keep electron-transport-chain components (such as cytochrome c) properly organized, reduce excess reactive oxygen species, and support more efficient ATP production. Because cardiolipin damage is a common feature of stressed or diseased mitochondria, the peptide is being studied wherever mitochondrial dysfunction is central.
Why people research it
- Barth syndrome, an ultra-rare X-linked disorder of cardiolipin metabolism causing cardiomyopathy and muscle weakness
- Primary mitochondrial myopathy, where genetic defects impair muscle energy production
- Dry age-related macular degeneration and geographic atrophy, where photoreceptor mitochondrial decline is implicated
- Heart failure and ischemia-reperfusion injury, where preserving mitochondrial function may protect cardiac tissue
- Broader interest in mitochondrial decline as a driver of aging and fatigue
Human evidence
SS-31/elamipretide has an unusually deep human dataset for a peptide, but the results are genuinely mixed. In primary mitochondrial myopathy, the pivotal phase 3 MMPOWER-3 trial (N=218) did NOT meet its co-primary endpoints (6-minute walk distance and a fatigue score). In Barth syndrome, the randomized portion of the TAZPOWER trial also failed its primary endpoints, but a long-term open-label extension reported sustained functional and cardiac improvements, and on the strength of an intermediate strength endpoint the FDA granted accelerated (conditional) approval in September 2025 (brand name Forzinity) for Barth syndrome in patients weighing at least 30 kg. In dry AMD, the phase 2 ReCLAIM-2 trial missed its primary visual and geographic-atrophy endpoints while showing a secondary signal on photoreceptor (ellipsoid zone) preservation. Earlier heart-failure and ischemia work (Bendavia/EMBRACE STEMI era) likewise did not deliver positive pivotal results. Because most primary endpoints were not met and the single approval is accelerated/conditional and disease-specific, the overall human evidence is best described as limited rather than strong, especially for any general wellness, longevity, or energy use, for which there is no approval and no convincing controlled human data.
Animal / lab evidence
Preclinical and in vitro work is extensive and consistently supportive: SS-31 reduces mitochondrial reactive oxygen species, preserves cristae structure and membrane potential, protects against ischemia-reperfusion injury, and improves cardiac and skeletal-muscle mitochondrial function in animal models. These mechanistic and animal findings are the foundation of the cardiolipin-binding model and motivated the human program, but they have translated only partially and inconsistently into clinical benefit.
Key studies
Each summary explains the design, what was found, and what it doesn't prove.
In the largest and most rigorous trial of SS-31 for inherited muscle mitochondrial disease, the peptide failed to beat placebo on walking distance or fatigue, which were the main goals. It was safe, but it did not work for the trial population as a whole.
In this tiny but important Barth syndrome study, SS-31 did not beat placebo in the strictly controlled phase. Over years of open-label use, patients improved on walking and heart measures, but without a comparison group those later gains are harder to trust. This program nonetheless supported the drug's 2025 accelerated approval for Barth syndrome.
For dry macular degeneration, SS-31 did not improve vision or slow the main measure of retinal damage compared to placebo. There was a hint it might protect photoreceptor structure, but that is an indirect marker, not proven vision benefit.
Researchers reanalyzed the failed mitochondrial myopathy trial and found that one genetic subgroup may have benefited. This is a clue, not proof, and a new dedicated trial was launched to test it properly.
This review explains why SS-31 was designed and how it targets mitochondria via cardiolipin. It is a useful overview of the science, but it summarizes existing work rather than proving the peptide works in people.
History
SS-31 originated from the 'Szeto-Schiller' (SS) peptide series developed by Hazel Szeto and Peter Schiller. It was advanced clinically by Stealth BioTherapeutics as MTP-131, studied under the trial name Bendavia in cardiovascular ischemia, and later branded elamipretide across the MMPOWER, TAZPOWER, and ReCLAIM trial programs. After a regulatory path that included a complete response, it received FDA accelerated approval for Barth syndrome (as Forzinity) in September 2025, the first approval of a mitochondria-targeted peptide.
PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.
Related peptides
A central coenzyme in energy metabolism that has been studied as a supplement and IV therapy for aging, fatigue, and metabolic health.
A mitochondrial-encoded peptide studied for its role in metabolism, exercise capacity, and mitochondrial signaling.
A four-amino-acid peptide studied primarily in Russian and Eastern European research for longevity, sleep, and antioxidant effects.